Consistent with the ability of DDX39B loss to attenuate cytotoxicity, overexpression of DDX39B in U87 GBM cells resulted in decreased clonal survival following TMZ treatment compared to control (Fig. 4c). This evidence concerns the gene DDX39B and glioblastoma.